Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bulevirtide in Chronic Hepatitis Delta
2019-001213-17Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bulevirtide in hepatitis D (HDV) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Combined response at week 48. Started Apr 2019; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2019-001213-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001213-17.